Stock SUPN SUPERNUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Supernus Pharmaceuticals, Inc.

Equities

SUPN

US8684591089

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
27.77 USD -0.36% Intraday chart for Supernus Pharmaceuticals, Inc. -3.38% -4.04%
May. 08 Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q1 Revenue $143.6M, vs. Street Est of $145.8M MT
May. 08 Transcript : Supernus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Supernus Pharmaceuticals, Inc. Reiterates Financial Guidance for the Full Year 2024
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Supernus, M8 Pharmaceuticals Sign Licensing Deal for ADHD Drug Qelbree in Latin America
M8 Pharmaceuticals, an Acino Company, Signs an Exclusive Licensing Agreement with Supernus for Qelbree® (Viloxazine Xr) in Latin America
Supernus Pharmaceuticals, Inc. Announces Retirement of John M. Siebert from the Board of Directors
Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket
Supernus Pharmaceuticals, Inc. Announces a Regulatory Update for SPN-830
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease
Supernus Pharmaceuticals Insider Sold Shares Worth $511,677, According to a Recent SEC Filing
Supernus Pharmaceuticals Insider Sold Shares Worth $436,573, According to a Recent SEC Filing
Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Supernus Pharmaceuticals, Inc. Announces Executive Changes
Supernus Pharmaceuticals Signs License Deal With Knight Therapeutics for Qelbree in Canada
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree in Canada
US Consumer Advocacy Group Seeks to Strengthen Warnings on Botox Labeling
US Consumer group seeks stronger warnings on Botox, similar treatments
Supernus Pharmaceuticals Insider Sold Shares Worth $259,151, According to a Recent SEC Filing
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SUPN Stock
  4. News Supernus Pharmaceuticals, Inc.
  5. Other languages